La cadena de opciones muestra datos clave de las opciones de acciones de Conmed a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Conmed..

Conmed (NYSE:CNMD) Bolsa, Cadena de Opciones

Conmed

Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.

Conmed Corp

<p>As of Nov. 25, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.</p>
<p>The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. </p>
<p>Here's the latest list of major overbought players in this sector.</p>
<h3 class="wp-block-heading"><strong>Conmed Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>)</strong></h3>
<ul>
<li>On Oct. 30, Conmed reported quarterly earnings of $1.05 per share which beat the analyst consensus estimate of 99 cents per share. &#8220;Our third quarter results were largely in line with our expectations, and we remain focused on getting fully back on offense,&#8221; commented Curt R. Hartman, CONMED&#8217;s Chair of the Board, President, and Chief Executive Officer. &#8220;I am particularly proud of how our teams responded to the disruption from hurricanes Helene and Milton, which temporarily impacted our employees and facilities in the Southeast as well as many of our customers.&#8221; The company's stock gained around 21% over the past month and has a <a href="https://www.benzinga.com/quote/CNMD">52-week high of $117.27</a>.</li>
<li><strong>RSI Value:</strong> 70.45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li><strong>CNMD Price Action:</strong> Shares of Conmed gained 4.5% to close at $74.91 on Friday.</li>
</ul>
<h3 class="wp-block-heading"><strong>Madrigal Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>)</strong></h3>
<ul>
<li>On Oct. 31, Madrigal Pharmaceuticals reported better-than-expected third-quarter financial results. Bill Sibold, Chief Executive Officer of Madrigal, stated, &#8220;Our U.S. launch of Rezdiffra is progressing exceptionally well driven by the outstanding execution of our team. Growing adoption by prescribers, broader payer coverage and an increasing number of patients on therapy each contributed to the strong performance. This early success highlights the critical need for effective treatments for moderate to advanced NASH/MASH, which is expected to become the leading cause of liver transplants in the U.S.&#8221; The company's stock gained around 65% over the past month and<a href="https://www.benzinga.com/quote/MDGL"> has a 52-week high</a> of $368.29.</li>
<li><strong>RSI Value:</strong> 74.01</li>
<li><strong>MDGL Price Action:</strong> Shares of Madrigal Pharmaceuticals gained 5.5% to close at $347.45 on Friday.</li>
</ul>
<h3 class="wp-block-heading"><strong>Butterfly Network Inc </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>)</h3>
<ul>
<li>On Nov. 1, Butterfly Network reported better-than-expected quarterly financial results and issued FY24 revenue guidance above estimates. The company's stock gained around 78% over the past month and has a <a href="https://www.benzinga.com/quote/BFLY">52-week high</a> of $3.55.</li>
<li><strong>RSI Value:</strong> 72.56</li>
<li><strong>BFLY Price Action:</strong> Shares of Butterfly Network fell 1.4% to close at $3.24 on Friday.</li>
</ul>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></strong></li>
</ul>


News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

BFLY

CNMD

MDGL

Top 3 Health Care Stocks That May Dip This Month

<p>Needham  analyst Mike Matson   reiterates Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) with a Buy and maintains $97 price target.</p>


Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on Conmed, Maintains $97 Price Target

<p>Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) reported quarterly earnings of $1.05 per share which beat the analyst consensus estimate of $0.99 by 6.06 percent.  The company reported quarterly sales of $316.701 million which missed the analyst consensus estimate of $318.128 million by 0.45 percent.  This is a 3.98 percent increase over sales of $304.578 million the same period last year.</p>


Earnings

Earnings Beats

Earnings Misses

Conmed Q3 2024 Adj. EPS $1.05 Beats $0.99 Estimate, Sales $316.701M Miss $318.128M Estimate

Management

CONMED Says Curt R. Hartman Will Retire As President And CEO, Effective January 1, 2025; Patrick Beyer To Succeed Hartman

<p>Ratings for Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $87.83, along with a high estimate of $106.00 and a low estimate of $71.00. A decline of 7.55% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728065138_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The perception of Conmed by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$97.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$76.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$71.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$97.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$106.00</td>
<td>$107.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Conmed. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Conmed compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Conmed's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Conmed's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CNMD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Conmed analyst ratings.</strong></a></p>
<h2>Get to Know Conmed Better</h2>
<p>Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.</p>
<h3>Unraveling the Financial Story of Conmed</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Conmed's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>4.55%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Conmed's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>9.03%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Conmed's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>3.45%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Conmed's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.3%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Conmed's debt-to-equity ratio is below the industry average. With a ratio of <b>1.1</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Assessing Conmed: Insights From 6 Financial Analysts

Guidance

CONMED Sees Q3 Revenue $315M - $ 318M Vs $318.66M Est.; Adj. EPS Growth Exceeding Prior Of 9% - 11 %

<p><strong>CONMED Corporation</strong>&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cnmd#NYSE">CNMD</a>) delivered adjusted earnings per share of 98 cents in the second quarter of 2024, which beat the Zacks Consensus Estimate of 92 cents by 6.5%. The bottom line improved 18.1% from the year-ago quarter&#39;s level.</p>
<p>GAAP EPS for the quarter was 96 cents compared with 43 cents per share in the year-ago period.</p>
<p>The company&#39;s shares have lost 14.7% in the past six months against the&nbsp;industry&#39;s rise of 1.5%. The broader S&amp;P 500 Index has gained 11.7% in the same time frame.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/04/73071.jpg?v=1795590198" /></p>
<p>Image Source: Zacks Investment Research</p>
<h3>Revenues in Detail</h3>
<p>CONMED&#39;s revenues totaled $332.1 million, up 4.5% year over year. The top line missed the Zacks Consensus Estimate by 0.7%. At constant exchange rate (CER), revenues increased 5.2%.</p>
<p>CNMD&#39;s second-quarter sales were driven by strong growth in the United States as well as international markets. The second quarter witnessed steady surgical volumes. The performance of CONMED&#39;s BioBrace in the foot and ankle space seemed encouraging.</p>
<h3>Segmental Details</h3>
<p>Revenues in the Orthopedic Surgery segment totaled $139.5 million, down 0.9% from the year-ago quarter&#39;s level on a reported basis. At CER, revenues decreased 0.1%.</p>
<p>Sales declined 0.4% on a reported basis in the United States. Sales decreased 1.2% (up 0.1% at CER) from the prior-year quarter&#39;s level in the international markets.</p>
<p>Revenues in the General Surgery segment amounted to $192.6 million, up 8.9% year over year on a reported basis and 9.4% at CER. U.S. sales increased 8.9% year over year. International sales improved 8.8% on a reported basis (10.5% at CER).</p>
<h3>Sales by Geography</h3>
<p>Sales in the United States totaled $185.4 million, up 6.1% year over year. International sales amounted to $146.7 million, up 2.6% year over year on a reported basis and 4% at CER.</p>
<h3>Margins</h3>
<p>CONMED&#39;s gross profit improved 7.6% to $183.7 million. The gross margin improved 160 basis points to 55.3%.</p>
<p>Selling &amp; administrative expenses decreased 5.5% to $122.5 million. Research and development expenses rose 3.9% year over year to $14.1 million.</p>
<p>The company recorded an operating income of $47.1 million compared with $27.4 million in the prior year quarter. The operating margin was 14.2%, up 560 basis points.</p>
<h3>2024 Guidance Revised</h3>
<p>CONMED lowered its revenue and earnings guidance for 2024 based on incremental foreign currency headwinds.</p>
<p>The company expects revenues between $1.305 billion and $1.315 billion for 2024 compared with the prior guidance of $1.330 billion and $1.355 billion. The Zacks Consensus Estimate is currently pegged at $1.34 billion.</p>
<p>Adjusted EPS is expected to be in the range of $3.95&nbsp;to&nbsp;$4.02 compared with the prior guided range of $4.25&nbsp;to&nbsp;$4.35. The Zacks Consensus Estimate is currently pegged at $4.30.</p>
<h3>Our Take</h3>
<p>CONMED exited the second quarter of 2024 on a mixed note, wherein earnings beat the Zacks Consensus Estimate, but revenues missed the same. The second quarter witnessed the impact of supply-chain issues, primarily for the sports medicine and foot and ankle businesses within the Orthopedic segment. The issue is likely to continue, which is reflected in the company&#39;s lowered outlook for 2024.</p>
<p>However, healthy demand in the General Surgery business is likely to help offset supply-chain issues hurting Orthopedic sales. The company&#39;s early-phase new surgical robot, AirSeal, demonstrated faster growth compared to last year, and the trend is likely to continue in the second half of 2024.</p>
<div class="chart_embed">
<h3>CONMED Corporation Price, Consensus and EPS Surprise</h3>
<p><img alt="CONMED Corporation Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/cf/1722512995.png" style="height:265px; width:577px" title="" /></p>
<p>CONMED Corporation price-consensus-eps-surprise-chart | CONMED Corporation Quote</p>
</div>
<h3>Zacks Rank and Stocks to Consider</h3>
<p>Currently, CONMED carries a Zacks Rank #4 (Sell).</p>
<p>Some better-ranked stocks in the broader medical space are&nbsp;<strong>Universal Health Service</strong>&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>),&nbsp;<strong>Quest Diagnostics&nbsp;</strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>)&nbsp;and&nbsp;<strong>ABM Industries&nbsp;</strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abm#NYSE">ABM</a>). While Universal Health Service sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy) each.</p>
<p>Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.</p>
<p>Universal Health Service has gained 41.1% compared with the industry&#39;s&nbsp;34.8% rise so far this year.</p>
<p>Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.</p>
<p>Quest Diagnostics shares have gained 3.7% so far this year compared with the&nbsp;industry&#39;s&nbsp;10.2% rise</p>
<p>ABM Industries&#39; earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.</p>
<p>ABM&#39;s shares have risen 24.1% so far this year compared with the industry&#39;s&nbsp;11.9% increase.</p>
<p><a href="https://www.zacks.com/stock/news/2314520/conmed-cnmd-q2-earnings-beat-sales-rise-y-y-24-view-cut?cid=CS-BENZ-FT-analyst_blog|earnings_article-2314520">To read this article on Zacks.com click here.</a></p>


Health Care

General

CONMED Q2 Earnings Beat, Sales Rise Y/Y, '24 View Cut

<p>Across the recent three months, 6 analysts have shared their insights on Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Conmed, presenting an average target of $89.5, a high estimate of $107.00, and a low estimate of $71.00. Observing a downward trend, the current average is 7.42% lower than the prior average price target of $96.67. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722531878_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of Conmed among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$76.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$71.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$97.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$106.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$107.00</td>
<td>$107.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Conmed. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Conmed compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Conmed's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Conmed's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CNMD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Conmed analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Conmed</h2>
<p>Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.</p>
<h3>Conmed: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Conmed's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately <strong>5.69%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Conmed's net margin excels beyond industry benchmarks, reaching <strong>6.31%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Conmed's ROE excels beyond industry benchmarks, reaching <strong>2.33%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.86%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.16</strong>, Conmed adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Peeling Back The Layers: Exploring Conmed Through Analyst Insights

<p>Piper Sandler  analyst Matt O'Brien   maintains Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) with a Overweight and lowers the price target from $95 to $80.</p>


Piper Sandler Maintains Overweight on Conmed, Lowers Price Target to $80

<p>Stifel  analyst Rick Wise   maintains Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) with a Buy and lowers the price target from $88 to $76.</p>


Stifel Maintains Buy on Conmed, Lowers Price Target to $76

<p>Wells Fargo  analyst Vik Chopra   maintains Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) with a Equal-Weight and lowers the price target from $77 to $71.</p>


Wells Fargo Maintains Equal-Weight on Conmed, Lowers Price Target to $71

WIIM

CONMED shares are trading lower after the company reported worse-than-expected Q2 revenue results and lowered its FY24 guidance. Additionally, Needham lowered its price target on the stock from $106 to $97.

<p>Needham  analyst Mike Matson   maintains Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) with a Buy and lowers the price target from $106 to $97.</p>


Needham Maintains Buy on Conmed, Lowers Price Target to $97

CONMED Corporation Sees FY24 Adj. EPS  $3.95-$4.02 vs Prior Range Of $4.25-$4.35, Revenue $1.305B-$1.315B vs Prior Range Of $1.33B-$1.355B

<p>Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.91 by 7.69 percent.  The company reported quarterly sales of $332.097 million which missed the analyst consensus estimate of $332.325 million by 0.07 percent.  This is a 4.55 percent increase over sales of $317.652 million the same period last year.</p>


Conmed Q2 2024 Adj. EPS $0.98 Beats $0.91 Estimate, Sales $332.097M Miss $332.325M Estimate

<p>Needham  analyst Mike Matson   maintains Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) with a Buy and lowers the price target from $107 to $106.</p>


Needham Maintains Buy on Conmed, Lowers Price Target to $106

<p>Needham  analyst Mike Matson   reiterates Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) with a Buy and maintains $107 price target.</p>


Needham Reiterates Buy on Conmed, Maintains $107 Price Target

<p>Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.</p>
<p>When insiders purchase shares, it indicates their confidence in the company&#8217;s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.</p>
<p>Below is a look at a few recent notable insider purchases. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.</p>
<h3 class="wp-block-heading"><strong>CONMED</strong></h3>
<ul>
<li><strong>The Trade: CONMED Corporation </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) Chief Operating Officer Pat Beyer <a href="https://www.benzinga.com/quote/CNMD/analyst-ratings">acquired a total of 3,000 shares</a> at an average price of $68.30. To acquire these shares, it cost around $204,900.</li>
<li><strong>What's Happening:</strong> On April 24, Conmed reported better-than-expected first-quarter financial results.</li>
<li><strong>What CONMED Does:</strong> Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries.</li>
</ul>
<h3 class="wp-block-heading"><strong>Skyworks Solutions</strong></h3>
<ul>
<li><strong>The Trade:</strong> <strong>Skyworks Solutions, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) Director, Chairman, CEO and President Liam Griffin acquired a total of 11,142 shares at an average price of $90.00. To acquire these shares, it cost around $1 million.</li>
<li><strong>What's Happening:</strong> On April 30, Skyworks Solutions reported quarterly earnings of $1.55 per share which beat the analyst consensus estimate of $1.52 by 1.97%.</li>
<li><strong>What Skyworks Solutions Does:</strong> Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity.</li>
</ul>
<p>Don&#8217;t forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a></p>
<h3 class="wp-block-heading"><strong>Enphase Energy</strong></h3>
<ul>
<li><strong>The Trade:</strong> <strong>Enphase Energy, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) EVP, CFO Mandy Yang <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 4,000 shares</a>  at an average price of  $104.24. To acquire these shares, it cost around $416,972.</li>
<li><strong>What's Happening:</strong> On April 23, Enphase Energy reported worse-than-expected first-quarter financial results and issued second-quarter revenue guidance below estimates.</li>
<li><strong>What Enphase Energy Does:</strong> Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform.</li>
</ul>
<p>Read More: <a href="https://www.benzinga.com/news/earnings/24/05/38606910/investor-sentiment-increases-ahead-of-jobs-report-dow-jumps-over-300-points">Investor Sentiment Increases Ahead Of Jobs Report, Dow Jumps Over 300 Points</a></p>


Long Ideas

Insider Trades

ENPH

SWKS

$1M Bet On Skyworks Solutions? Check Out These 3 Stocks Insiders Are Buying

<p>JP Morgan  analyst Robbie Marcus   maintains Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) with a Overweight and lowers the price target from $115 to $75.</p>


JP Morgan Maintains Overweight on Conmed, Lowers Price Target to $75

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Trevi Therapeutics (TRVI – Research Report), Conmed (CNMD – Resea...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Trevi Therapeutics (TRVI), Conmed (CNMD) and Revance Therapeutics (RVNC)

Wells Fargo analyst Vik Chopra maintained a Hold rating on Conmed (CNMD – Research Report) on October 4. The company's shares closed last Friday at...

Wells Fargo Remains a Hold on Conmed (CNMD)

Wells Fargo analyst Vik Chopra maintained a Hold rating on Conmed (CNMD – Research Report) yesterday and set a price target of $71.00. Vik Chopra's...

Cautious Hold: Navigating Challenges and Uncertainty in Conmed's Outlook Amid Competitive and Operational Pressures

Reports Q3 revenue $316.7M, consensus $318.1M. "Our third quarter results were largely in line with our expectations, and we remain focused on gett...

Conmed reports Q3 EPS $1.05, consensus 99c

Consensus $3.99. Lowers FY24 revenue view to $1.30B-$1.305B from $1.305B-$1.315B, consensus $1.31B. Published first on TheFly – the ultimate source...

Conmed raises FY24 EPS view to $4.00-$4.05 from $3.95-$4.02

CONMED reports Q3 results

The latest announcement is out from Conmed ( ($CNMD) ). CONMED Corporation announced the appointment of Pat Beyer as President and CEO, effective J...

Conmed Announces New CEO Amid Strong Q3 Performance

CONMED Corporation 2024 Q3 - Results - Earnings Call Presentation

CONMED Corporation (CNMD) Q3 2024 Earnings Call Transcript

In a report released yesterday, Rick Wise from Stifel Nicolaus maintained a Buy rating on Conmed (CNMD – Research Report), with a price target of $...

Comments

Conmed

Conmed (CNMD) Opciones

Conmed (NYSE:CNMD) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL